Renzapride

Drug Profile

Renzapride

Alternative Names: ATL-1251; AZM 112; BRL-24924; Renzapride hydrochloride

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Alizyme; EndoLogic; GlaxoSmithKline
  • Class Benzamides; Gastrokinetics; Heterocyclic bicyclo compounds; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Gastroparesis
  • Discontinued Gastro-oesophageal reflux; Irritable bowel syndrome

Most Recent Events

  • 15 May 2018 Clinical trials in Gastroparesis in USA (PO) before May 2018
  • 18 Aug 2017 EndoLogic is seeking funds for development of renzapride as of 10 Aug 2017. www.endologicusa.com
  • 09 Aug 2017 EndoLogic announces intention to submit an IND application to US FDA for Gatroparesis in the fourth quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top